Labcorp (LH) said Monday that its blood test that detects Alzheimer's disease is now available after receiving clearance from the US Food and Drug Administration.

The company said its Elecsys pTau-217 test, developed by Roche Diagnostics, helps identify amyloid pathology associated with Alzheimer's disease in people aged 55 and older with signs, symptoms, or complaints of cognitive decline.

The test, according to Labcorp, is the only FDA-cleared single-biomarker blood test to rule in and rule out amyloid pathology in specialty and primary care settings.

Labcorp said it expects the test to be available nationwide in the coming months.